Zhitong Finance App News, Buchang Pharmaceutical (603858.SH) issued an announcement. Recently, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (“Luzhou Buchang”), the holding subsidiary of the company, received the “Notice of Termination of Drug Registration Application” issued by the State Drug Administration regarding “Injectable Effipotin α (Generic Name Approved by the National Pharmacopeia Commission: injectable erythromycin α)”, agreeing to Luzhou Buchang to withdraw the registration application for the drug.

Injectable erythropoietin alpha is suitable for treating anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin treatment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.